

Validation data for Anti-CoV2RBD-cas-mIgG2a

<https://www.invivogen.com/sars2-spike-regn-mab>

For research use only

Version 21F11-NJ

Anti-CoV2RBD-cas-mIgG2a and Anti-CoV2RBD-imd-mIgG2a are recombinant monoclonal antibodies (mAbs) featuring the variable region of the REGN10933 (aka Casirivimab) and REGN10987 (aka Imdevimab) human mAbs, respectively. They both feature a mouse IgG2a constant region and they specifically target the SARS-CoV-2 Spike receptor-binding domain (RBD). The binding of these antibodies has been validated by ELISA, using coated SARS-CoV-2 Spike-RBD proteins derived from the Wuhan (**Figure 1A**), United Kingdom (**Figure 1B**), and South-Africa (**Figure 1C**) variants, as well as an Anti-mIgG2a-HRP secondary antibody. CR3022-derived Anti-Spike-RBD-mIgG2a and Anti- β Gal mIgG2a have been used as controls.

Binding of Anti-CoV2RBD-cas-mIgG2a and Anti-CoV2RBD-imd-mIgG2a to RBD variants




Figure 1: SARS-CoV-2 Spike-RBD proteins (3 μ g/ml) derived from the Wuhan (**A**), United Kingdom (U.K.) (**B**), or South-Africa (S.A.) (**C**) variants were coated on ELISA plates overnight. A 3-fold serial dilution of Anti-CoV2RBD-imd-IgG2a (red curve), Anti-CoV2RBD-cas-mIgG2a (orange curve), CR3022-derived Anti-Spike-RBD mIgG2a (back curve), of Anti- β Gal-mIgG2a antibodies (grey curve) was performed for the capture step. A HRP-labelled Anti-mIgG2a antibody (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3-622-34-80

E-mail: info@invivogen.com